RecruitingNot ApplicableNCT06214598

Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors

Anti-Inflammatory Dietary Intervention in Breast Cancer Patients Receiving Aromatase Inhibitors

Sponsor

University of Belgrade

Enrollment

90 participants

Start Date

Mar 1, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

This project aims to decrease undesirable side effects and increase qulaity of life of aromatase inhibitors therapy in breast cancer survivors, by anti-inflammatory diet or supplementation.

Eligibility

Sex: FEMALEMin Age: 45 YearsMax Age: 70 Years

Inclusion Criteria7

Age: 45 to 70 years
Postmenopausal women
Histologically confirmed BRC, stage I to IIIa
ER positive /HER2 negative
Application of adjuvant hormone therapy with aromase inhibitors: 6 to 30 months
Body mass index from 20 to 34.9 kg/m 2
Able to understand the requirements of the study and provide written information consent

Exclusion Criteria14

Metastatic or locally advanced disease
HER2-positive tumors
Presence of other malignant or serious chronic diseases
Active infections
Previous stroke or heart attack,
Rheumatoid arthritis and other types of autoimmune diseases
Presence of a significant neurological deficit
Dementia
Allergy to the ingredients of the dietary preparation or to fish, fish oil and nuts fruits.
Allergies to evening primrose oil or other oils containing gamma-linolenic acid (borage, black currant)
Use of lipid-lowering drugs (statins, Normolip)
Current use of warfarin or other anticoagulants
Corticosteroid therapy for the last month
Use of dietary supplements based on fish oil, evening primrose, and flaxseed oils, omega 3-6-9 fatty acids, multivitamins with added omega-3 of fatty acids 3 months before the start of the study